HIV-1 is extremely dangerous if left untreated. Without medication, it progressively destroys the immune system and advances to AIDS, typically within about 10 years. People with AIDS who receive no treatment survive an average of 3 years. In 2022 alone, roughly 630,000 people worldwide died from HIV-related causes. With modern treatment, however, the picture changes dramatically: life expectancy for people on antiretroviral therapy now approaches that of people without HIV.
How HIV-1 Attacks the Immune System
HIV-1 specifically targets CD4 cells, a type of white blood cell that coordinates the body’s immune response to infections. The virus binds to the surface of a CD4 cell, fuses with it, and inserts its own genetic material into the cell’s DNA. Once embedded, it hijacks the cell’s machinery to produce copies of itself. A single infected CD4 cell can produce around 10,000 new virus particles during the acute stage of infection. Those new copies burst out of the cell, destroying it in the process, and go on to infect more CD4 cells.
Over time, the body loses CD4 cells faster than it can replace them. As the count drops, the immune system becomes increasingly unable to fight off infections and cancers that a healthy body would handle easily.
HIV-1 vs. HIV-2
HIV-1 is the more dangerous of the two types. It produces higher levels of circulating virus in the bloodstream, spreads more efficiently, and progresses to AIDS faster. HIV-2, found mainly in parts of West Africa, causes lower viral loads and advances more slowly. The vast majority of HIV infections worldwide are HIV-1.
Stages of Untreated Infection
HIV-1 progresses through three stages when no treatment is given.
Acute infection develops within 2 to 4 weeks of exposure. Many people experience flu-like symptoms: fever, sore throat, swollen lymph nodes, rash, and muscle aches. During this window the virus is replicating rapidly and the person is highly infectious, often before they realize they’ve been exposed.
Chronic infection follows and can last a decade or longer. The virus is still active but reproduces at much lower levels. Most people feel fine during this stage and may have no symptoms at all, which is why it’s sometimes called clinical latency. Without testing, many people don’t know they’re infected. The virus continues quietly depleting CD4 cells throughout this period.
AIDS is the final stage, reached when the immune system is severely damaged. The body becomes vulnerable to opportunistic infections and cancers that rarely threaten people with healthy immune systems, including certain types of pneumonia, tuberculosis, and aggressive lymphomas. Without treatment at this point, survival averages about 3 years.
Long-Term Risks Even With Treatment
Modern antiretroviral therapy suppresses the virus to undetectable levels and allows CD4 cells to recover. But HIV-1 isn’t completely harmless even when well controlled. The virus triggers chronic, low-grade inflammation that persists despite successful treatment. This ongoing immune activation has been linked to a higher risk of cardiovascular disease, diabetes, certain cancers, bone density loss, and chronic lung disease.
These risks exist even in people whose immune systems have recovered to healthy CD4 counts. The inflammation appears to be a lasting consequence of HIV’s presence in the body, and it means people living with HIV face a somewhat elevated risk of age-related diseases compared to the general population. Researchers are still working to fully understand and manage this residual inflammation.
How Treatment Changes the Outlook
The difference between treated and untreated HIV-1 is enormous. Antiretroviral therapy, taken daily, can reduce the virus to undetectable levels in the blood within a few months. At that point, the immune system stabilizes and begins to rebuild. Life expectancy for someone who starts treatment early and stays on it now approaches that of someone without HIV.
There’s another major benefit: a person with an undetectable viral load has zero risk of transmitting HIV to sexual partners. This principle, known as Undetectable = Untransmittable (U=U), has been confirmed in large studies and is recognized by the CDC. It means effective treatment doubles as prevention.
Prevention Options
For people who don’t have HIV but are at higher risk of exposure, pre-exposure prophylaxis (PrEP) is highly effective. Clinical trials have shown PrEP reduces the risk of acquiring HIV by 86% to 92% when taken consistently. Real-world data confirms this: people who maintained a high level of PrEP use saw effectiveness reach 93%. The key word is consistency. In younger users and those who frequently missed doses or stopped taking the medication, effectiveness dropped sharply, in some cases providing little to no protection.
Condoms, clean needle programs, and post-exposure prophylaxis (a short course of medication taken after a potential exposure) are additional layers of prevention that significantly reduce transmission risk.
Why Early Testing Matters
HIV-1’s danger is closely tied to how late it’s caught. Someone diagnosed during acute or early chronic infection and started on treatment promptly can expect decades of healthy life. Someone diagnosed only after developing AIDS faces a much harder road, with more damage to reverse and a higher risk of serious complications. Because chronic HIV infection can be completely symptomless for years, routine testing is the only reliable way to catch it early. The CDC recommends that everyone between 13 and 64 be tested at least once, with more frequent testing for those at higher risk.